DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

NCT00298298 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Suspended until capitalization is completed

Conditions

Non-Small Cell Lung Cancer - Completely Resectable

Interventions

BIOLOGICAL: L-Vax: Autologous, DNP-Modified NSCLC Vaccine

Sponsor

AVAX Technologies